Enzymes that consume and produce nucleoside polyphosphate (NPP) anions represent major targets in drug discovery. For example, protein kinases are one of the largest classes of drug targets in the fight against cancer. The accurate determination of enzyme kinetics and mechanisms is a critical aspect of drug discovery research. To increase confidence in the selection of lead drug compounds it is crucial that pharmaceutical researchers have robust, affordable assays to measure enzyme activity accurately. We present a simple, sensitive microplate assay for real-time monitoring of a range of pharmaceutically important enzyme reactions that generate NPP anions, including kinases and glycosyltransferases. Our assay utilises a single, stable europium(III) complex that binds reversibly to NPP anions, signalling the dynamic changes in NPP product/substrate ratio during an enzyme reaction using time-resolved luminescence. This supramolecular approach to enzyme monitoring overcomes significant limitations in existing assays, obviating the need for expensive antibodies or equipment, chemically labelled substrates or products and isolation or purification steps. Our label and antibody-free method enables rapid and quantitative analysis of enzyme activities and inhibition, offering a potentially powerful tool for use in drug discovery, suitable for high-throughput screening of inhibitors and accurate measurements of enzyme kinetic parameters.
Introduction
Monitoring enzymatic activity is of fundamental importance to industrial and biomedical researchers. It enables enzyme kinetics and thus mechanisms to be determined; a critical rst step in the discovery of potent enzyme inhibitors and activators. 1 Nucleoside polyphosphate (NPP) anions are involved in a number of pharmaceutically important enzyme reactions including kinases, GTPases and glycosyltransferases (GTs). Protein kinases catalyse the phosphorylation of amino acid residues (e.g. Ser, Thr, Tyr) on proteins, converting ATP into ADP in the process. Misregulation of kinase activity is a primary cause of many types of cancer; therefore, protein kinases are a major target for oncology drug discovery.
2 GTs catalyse the transfer of a sugar from a donor (e.g. UDP-sugar) to a variety of acceptors (e.g. oligosaccharides, proteins, lipids) 3 and have been identied as promising drug targets to treat tuberculosis and metabolic disorders; yet only two GT inhibitors are in clinical use. 4 Progress in GT inhibitor development is limited by the lack of robust, label-free tools for conducting highthroughput screening (HTS) assays. Currently, there is no lowcost method available for real-time monitoring of kinase or GT reactions, 4 limiting progress in understanding their mechanisms and inhibition, increasing the risk of late-stage clinical failure of drug candidates.
The majority of commercial enzyme assays (ADPGlo™, HTRF®, DELFIA® for kinases, UDPGlo™ for GTs), are restricted to single end-point measurements, making the accurate determination of kinetic parameters (K m , k cat ) difficult and time consuming, particularly for enzymes with complicated mechanisms. Many enzyme assays require expensive antibodies to detect a specic product and require isolation and washing steps preventing real-time measurements. 5 Other assays remove the need for antibodies but require substrates with luminescent or radioactive labels. [6] [7] [8] For example, peptide-sensor conjugates have been used to probe kinase activity, involving chemical modication of a peptide substrate with phosphate recognition groups, which signal phosphorylation usually by a FRET interaction. 9 However, this approach precludes the use of natural substrates, increasing uncertainty in 'hit' compounds. The high cost of these reagents and time required to validate the assays places a strain on drug development. To increase productivity earlier in the drug discovery process, a low-cost, label and antibody-free method for real-time reporting of enzyme activity is needed.
Synthetic host molecules that bind selectively to a target analyte offer an attractive alternative approach for monitoring enzyme reactions. Cucurbituril and calixarene hosts have been employed successfully in supramolecular enzyme assays.
10,11
Cucurbituril hosts bind ammonium ions selectively, displacing a uorescent dye from the host, allowing real-time analysis of methyltransferase and demethylase reactions.
12
However, cucurbituril hosts do not bind to phosphate derivatives and therefore cannot be used for monitoring enzymes such as kinases, GTPases or GTs. Kinase activity has been monitoring by using cavitand/uorophore pairs to discriminate between phosphopeptides in an array-based format. 13, 14 An alternative approach is to use a single receptor that can discriminate between NPP anions, whilst showing negligible binding to phosphorylated peptides. This could provide a universal assay platform for real-time monitoring of NPP-anion utilising enzyme reactions.
The creation of receptors that can discriminate between NPP anions (e.g. ATP, ADP, GTP, UDP) is particularly challenging due to similarities in anion structure, size and charge. 15 Hence, examples of NPP-selective receptors are quite rare; the majority utilise positively charged recognition groups to engage in electrostatic interactions with the phosphate groups of NPPs. Dinuclear Zn(II) complexes have shown high affinity for NPPs, pyrophosphate and phosphorylated peptides, 16, 17 and have been used for both end-point and real-time monitoring of enzyme reactions. 18, 19 However, such receptors exhibit similar affinities for tri-and diphosphate anions, and oen induce similar uorescence responses. Additionally, the uorescence is shortlived and can be difficult to distinguish from the background uorescence of biological substrates, decreasing the signal to noise ratio. 
28,29
However, probes capable of sensing larger NPP anions are quite rare and usually act as 'on-off' probes, where anion binding causes quenching of luminescence by displacing the sensitizing 'antenna', or by energy transfer to the nucleotide base. Notably, Pierre developed an ATP-selective Tb(III) complex, wherein p-p stacking of the adenosine base and phenanthridine antenna causes luminescence quenching.
32,33
We Signalling the ADP/ATP ratio in microplate format using timeresolved luminescence 34 to record time-resolved luminescence measurements of the DJ ¼ 2 band (integration time ¼ 60-400 ms), gating out short-lived uorescence from biological uo-rophores (e.g. tryptophan and tyrosine residues on proteins). Crucially, a time-resolved measurement gave a linear emission response to the ADP/ATP ratio ( Fig. 2b) with signicantly increased signal to noise, allowing the luminescence signal to be correlated to the course of a kinase reaction. To conrm this, we used hexokinase as a model enzyme. Hexokinase is a wellstudied, commercially available metabolic kinase that catalyses the phosphorylation of glucose in the rst step of glycolysis (Fig. 2a) , converting ATP to ADP in the process (Fig. 2a) . By following the increase in the time-resolved DJ ¼ 2 emission intensity (Fig. 2c) , the enzyme reaction was monitored as a function of time as the ADP/ATP ratio increases, conrming our ability to monitor kinase reactions in a microplate format. Decreasing the concentration of hexokinase by a factor of two resulted in a decrease in the initial rate of luminescence intensity increase by the same order (Fig. 2d) .
To If (Fig. S3-S22 †) . Importantly, the kinase reaction could be performed over a wide ATP concentration range (0.1-5 mM), including physiological ATP levels, and is thus suitable for monitoring low activity kinases, an area of increasing pharmaceutical interest but where existing assays offer very little. 40 and is a target of several cancer drug discovery programmes. 41 Initially, we monitored the AurA reaction at different enzyme concentrations (Fig. 3a) . As AurA catalyses the phosphorylation of the substrate, kemptide (LRRASLG), there is an increase in the time-resolved DJ ¼ 2 emission intensity of [Eu.1] + , as observed in the model hexokinase reaction. Increasing the AurA concentration lead to a faster emission intensity increase, consistent with an increase in reaction rate.
Monitoring kinase inhibition and determining kinetic parameters
An essential feature of enzyme assays is the ability to derive accurate kinetic parameters, such as substrate K m values and inhibition data (IC 50 /K i values). This is key to understanding enzyme mechanisms and to inform the development of new inhibitors. With this in mind, we varied the substrate concentration for both hexokinase and Aurora A (fructose and kemptide, respectively). For the different substrate concentrations, the initial rate was calculated as the change in intensity per minute over the rst $25% of the reaction, tting the data to a Michaelis-Menten equation (Fig. S23 † and 3b) . This data allowed substrate K m values to be determined, giving 252 AE 43 mM for fructose/hexokinase and 176 AE 29 mM for kemptide/ AurA. The calculated values are comparable to the literature (330 mM for each substrate).
42-44
Next, we evaluated the ability of our probe to perform quantitative analysis of inhibition. First, we added various known AurA inhibitors and, in all cases, observed a decrease in the enzyme reaction rate compared to in the absence of inhibitor ( Fig. 3c and d) . Addition of TPX2, an Aurora A activator, lead to an increase in the enzyme reaction rate (Fig. S24 †) , as expected. The effect of one of the inhibitors, staurosporine, was examined in more detail, conducting an inhibitor titration to obtain an IC 50 of 9.32 AE 0.46 mM (Fig. 3e) , comparable with previously reported values obtained under similar conditions (2.9 AE 0.5 mM). 45 This was further corroborated using a commercial assay, ADP-Glo, generating an IC 50 for staurosporine (Fig. S25 †) + . ADP-Glo functions by indirectly measuring the concentration of ADP formed in the kinase reaction. This involves running the reaction for a suitable time period, stopping the reaction and removing the unconsumed ATP, then converting the ADP to ATP and measuring its concentration by a chemiluminescent luciferase reaction. ADPGlo serves as a good comparison to our assay because it measures the ADP formed; however, the measurements are not taken in real-time, and several steps need to be performed at certain time points to obtain reliable data. Consequently, ADPGlo converts a 15 minute enzyme reaction into a 2 hour procedure. In comparison, our single Eu(III) probe can monitor the reaction directly and continuously, enabling reliable kinetic parameters to be obtained more rapidly and with fewer steps, taking only the time of the enzyme reaction. These features offer the potential for increasing productivity and in drug discovery programmes, compared to current commercial assays.
Monitoring the conversion between other NPP anions
The ability of [Eu.1] + to sense and differentiate other nucleoside polyphosphate anions (Fig. S26-S27 †) , offers the potential to monitor a wide variety of pharmaceutically important enzyme reactions, particularly those involving the formation of NDP or NMP anions, as these anions induce large enhancements in Eu(III) emission intensity. To this end we simulated a range of NPP anion utilising enzymes, including NTPases, pyrophosphohydrolases and glycosyltransferases ( Table 2 , Fig. S28 -S42 †). In most cases these simulations gave a linear increase in the time-resolved DJ ¼ 2 emission intensity, implying the ability to prole a wide variety of NPP anion-utilising enzymes using a single luminescent probe.
To demonstrate the ability to monitor NPP anions possessing other nucleotide bases we used pyruvate kinase, which catalyses the conversion of ADP + phosphoenolpyruvate (PEP) to ATP + pyruvate but can use other NDP substrates. We monitored pyruvate kinase reactions (Fig. S33 †) using different NDP anions (A, C, G, U and dA), observing the expected decrease in luminescence intensity (for all but CDP) over time as the NDP anion is converted to the corresponding NTP anion, dephosphorylating PEP in the process. Increasing the enzyme concentration gave a faster decrease in emission intensity, consistent with an increase in reaction rate. In the case of CDP, the decrease in
+ emission intensity is comparable to that of the photobleaching experiment (in the absence of enzyme), consistent with CDP being a poor substrate for pyruvate kinase.
46

Monitoring glycosyltransferases
An important enzyme class for biological and therapeutic applications is the glycosyltransferases (GTs). GTs catalyse the transfer of saccharide units from a glycosyl donor (e.g. a UDPsugar) to an acceptor (e.g. oligosaccharide) (Fig. 4a) . 3, 4 GTs are involved in a range of biological processes underpinning health and disease, including cell signalling, adhesion and cell wall biosynthesis, and thus represent attractive druggable targets. However, progress in GT inhibitor development is restricted by the lack of label-free tools for conducting HTS assays. We simulated GT reactions using two different glycosyl donors, UDP-glucose and UDP-galactose, which are converted to UDP during the reaction (Fig. 4b and S34-S37 †) . We used glucose and maltose as example acceptor and product sugars, having shown that various mono-and disaccharides at 10 mM concentration have very little effect on the luminescence of [Eu.1] + (Fig. S43 †) . Varying the ratio of UDP/UDP-sugar in the presence of [Eu.1] + (Fig. 4b) to the progress of a GT reaction.
Next, the probe was used to monitor the activity of the bacterial glycosyltransferase, LgtC, a promising target for the discovery of novel antibiotics. LgtC catalyses the transfer of galactose from UDP-galactose to a lactose acceptor, producing UDP in the process. When this reaction is performed in the presence of [Eu. 1] + there is an increase in the time-resolved luminescence intensity of the DJ ¼ 2 band over time (Fig. 4c) . Moreover, the initial rates of the reaction depended linearly on the concentration of enzyme used (Fig. 4d) . This demonstrates the ability of [Eu.1] + to monitor another important class of NPPutilising enzymes. Next, the probe was used to monitor the activity of the bacterial glycosyltransferase, LgtC, a potential target for the discovery of novel antibiotics. LgtC catalyses the transfer of galactose from UDP-galactose to a lactose acceptor, producing UDP in the process. When this reaction is performed in the presence of [Eu. 1] + there is an increase in the time-resolved luminescence intensity of the DJ ¼ 2 band over time (Fig. 4c) . Moreover, the initial rates of the reaction depended linearly on the concentration of enzyme used (Fig. 4d) . This demonstrates the ability of [Eu.1] + to monitor another important class of NPPutilising enzymes.
Monitoring phosphodiesterases
Cyclic nucleotide phosphodiesterases (PDEs) represent another class of drug target that are difficult to screen. Cyclic nucleotide PDEs catalyse the conversion of the key signalling molecules, cAMP and cGMP, to AMP and GMP (Fig. 5a) , and hence are important in cell signalling. 47 Having shown previously that [Eu. 1] + binds relatively strongly to AMP (log K a ¼ 3.4), and that both AMP and GMP induce distinctive emission responses compared to those of cAMP and cGMP, we decided to simulate each of these PDE reactions. Upon increasing the NMP/cNMP ratio there is a linear increase in time-resolved emission intensity of [Eu.1] + (Fig. 5b and c) . Fig. 5e and g ), as anticipated on addition of an enzyme activator.
Monitoring sequential enzyme reactions
A benet of monitoring enzyme reactions in real-time, rather than using single-point detection, is that we can monitor sequential enzyme reactions, enabling a biosynthetic pathway to be followed. This is important not only in drug discovery but also in large-scale biosynthesis, where knowledge of the optimum time to add enzymes and substrates is crucial for maximising product yield and process efficiency. To demonstrate the principle of monitoring sequential enzyme reactions, we used two previously studied enzymes, hexokinase (HK) and pyruvate kinase (PK), which are involved in the same metabolic pathway, glycolysis. Hexokinase catalyses the conversion of ATP to ADP during the phosphorylation of glucose, while pyruvate kinase converts ADP back to ATP (along with dephosphorylation of PEP) (Fig. 6a) . We monitored this reaction sequence in one pot using [Eu.1] + . Initially the emission intensity increased as ATP is converted to ADP by hexokinase, followed by a decrease in luminescence as ADP is converted back to ATP by pyruvate kinase (Fig. 6b) . Decreasing the concentration of pyruvate kinase decreased the rate of conversion of ADP back to ATP and hence the rate of decrease in Eu(III) luminescence, as well as yielding a higher maximal intensity response. In the absence of hexokinase there is very little change in luminescence compared to the bleaching experiment (no hexokinase nor pyruvate kinase present), whereas in the absence of pyruvate kinase but presence of hexokinase (yellow line) there is a rapid initial intensity increase as the hexokinase converts ATP to ADP, followed by a plateauing of the signal as the ADP cannot be converted back to ATP (some photobleaching is observed in this case). Reversing the enzyme reaction sequence, by starting with ADP and monitoring its conversion to ATP by pyruvate kinase, followed by the hexokinase catalysed conversion of ADP back to ATP, gave the opposite luminescence response: an initial decrease followed by an increase in [Eu. 1] + emission (Fig. S45 †) . These experiments highlight the capability of our supramolecular enzyme assay for monitoring sequential enzyme reactions in one solution, a feature that is not possible using commercial end-point assay technologies.
Conclusions
In discriminate between nucleoside tri-, di-and monophosphate anions allowed the enzymatic production of different NPP anions to be monitored in a convenient luminescence-based increase-in-signal format.
The robustness of our assay platform is illustrated by its ability to operate in a wide-range of biologically relevant conditions, determine accurate kinetic parameters (K m , IC 50 ) and monitor sequential enzyme reactions. Our Eu(III) probe offers signicant advantages over existing assay technologies, including: (1) label-and antibody-free detection; (2) a timeresolved luminescent signal that eliminates background uo-rescence; and (3) real-time measurements that enable both qualitative and quantitative analysis of enzyme activity, selectivity and inhibition. Moreover, our microplate assay can be performed at physiological concentrations of NPP anions (e.g. 1-5 mM ATP for kinase assay) and thus can be used to screen for inhibitors of low activity enzymes, a feature that is not possible using current assay platforms.
By utilising a single molecular probe, our assay has the potential to simplify HTS screening processes signicantly, extending the breadth of substrate-specic assays, and allowing a wide range of enzymes and substrates to be screened under identical assay conditions. Moreover, the ability to study natural substrates could facilitate a better understanding of enzyme inhibition mechanism, reducing the possibility of drug candidates passing early development stages, only to fail at a later, more costly phase.
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